Remo CRO


Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine

01.22 2019.

London UK; Philadelphia US; Geneva Switzerland – January 16, 2019 — GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure… Details

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes

01.22 2019.

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital… Details

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

01.22 2019.

HIGH POINT, N.C.–(BUSINESS WIRE)–Jan. 16, 2019– vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small… Details

Stem cell transplant slows down MS progression

01.19 2019.

Clinical trial compares stem cell transplantation with existing disease-modifying therapies and finds that the former is more effective at slowing down MS. Details

Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis

01.16 2019.

Seattle, WA and Charleston, S.C. — January 14, 2019 — Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with SPI-1005 is… Details

New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder

01.16 2019.

PARIS, Jan. 9, 2019 /PRNewswire/ — The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare,… Details